Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clinitech LaboratoryBOM:544220 -7.50%38 Return-on-Tangible-Equity is 2.80% as of Mar. 2026, which is 87% below its 10-year median of 21.97. GuruFocus rates BOM:544220 with a GF Score™ of 38/100. The stock has 6 warning signs investors should review. Among 188 Medical Diagnostics & Research companies, Clinitech Laboratory ranks better than 60.11% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Clinitech Laboratory's annualized net income for the quarter that ended in Mar. 2026 was ₹2.29 Mil. Clinitech Laboratory's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹81.77 Mil. Therefore, Clinitech Laboratory's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 2.80%.
The historical rank and industry rank for Clinitech Laboratory's Return-on-Tangible-Equity or its related term are showing as below:
BOM:544220'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 5.15 Med: 21.97 Max: 31.71
Current: 5.15
During the past 6 years, Clinitech Laboratory's highest Return-on-Tangible-Equity was 31.71%. The lowest was 5.15%. And the median was 21.97%.
BOM:544220's Return-on-Tangible-Equity is ranked better than 60.11% of 188
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.455
vs BOM:544220: 5.15
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Clinitech Laboratory Return-on-Tangible-Equity Related Terms
Clinitech Laboratory Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Clinitech Laboratory's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:544220 vs TMO, DHR, IDXX: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, Clinitech Laboratory's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinitech Laboratory Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Clinitech Laboratory's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Clinitech Laboratory's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 2.80% mean?
Clinitech Laboratory (BOM:544220) has a Return-on-Tangible-Equity of 2.80% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Clinitech Laboratory and its competitors. This is 87% below median its historical median of 21.97. Over the past decade, Clinitech Laboratory's Return-on-Tangible-Equity has ranged from 5.15 to 31.71. According to the industry distribution chart, Clinitech Laboratory ranks #75 out of 188 companies in the Medical Diagnostics & Research industry, placing it in the top 39.9%.
Is Clinitech Laboratory's Return-on-Tangible-Equity too high?
Clinitech Laboratory's current Return-on-Tangible-Equity of 2.80% is 87% below median its 10-year median of 21.97. Over the past 10 years, this metric has ranged from a low of 5.15 to a high of 31.71. The Medical Diagnostics & Research industry median Return-on-Tangible-Equity is 0.46. Clinitech Laboratory's value of 2.80% is 515.4% above this industry median. Based on the distribution chart, Clinitech Laboratory ranks #75 out of 188 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Clinitech Laboratory has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Clinitech Laboratory's Return-on-Tangible-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Clinitech Laboratory ranks #75 out of 188 companies for Return-on-Tangible-Equity. This puts Clinitech Laboratory in the upper half of its industry. The industry median Return-on-Tangible-Equity is 0.46. Clinitech Laboratory's value of 2.80% is 515.4% above this benchmark. Historically, Clinitech Laboratory's own Return-on-Tangible-Equity has ranged from 5.15 to 31.71 over the past decade. While the company's 10-year median is 21.97 vs. the industry median of 0.46, Clinitech Laboratory has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
The median Return-on-Tangible-Equity among Medical Diagnostics & Research companies is 0.46, based on 188 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clinitech Laboratory's current Return-on-Tangible-Equity of 2.80% is 515.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Clinitech Laboratory and its competitors. For the Medical Diagnostics & Research industry, the median Return-on-Tangible-Equity is 0.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clinitech Laboratory's current Return-on-Tangible-Equity is 2.80%, which is 87% below median its own 10-year median of 21.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinitech Laboratory stock overvalued right now?
Clinitech Laboratory (BOM:544220) has a current Return-on-Tangible-Equity of 2.80%. The current Return-on-Tangible-Equity is 2.80%, which is 87% below median its 10-year median of 21.97 and 515.4% above the Medical Diagnostics & Research industry median of 0.46. Clinitech Laboratory's overall GF Score™ is 38/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Clinitech Laboratory (BOM:544220), the current Return-on-Tangible-Equity is 2.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Clinitech Laboratory Ltd is an Indian diagnostic and healthcare services provider company. It operates a network of diagnostic centers in Thane and Navi Mumbai and offers various medical tests across multiple specialties, including biochemistry, immunology, hematology, molecular biology, serology, microbiology, and histopathology. It serves individual patients as well as corporate clients, aiming to provide affordable and comprehensive diagnostic solutions.
38GF Score
Get the complete analysis for BOM:544220
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544220 has been successfully added to your 
